Ron Demuth
Torrey Pines Investment (TPI) was founded in 22 and is based in San Diego CA. The firm has raised two funds and also invests in drug development via a partnership with BioMotiv. TPI makes venture-stage minority equity investments and prefers act as a co-investor but also leads rounds on occasion. The firm invests internationally.
Torrey Pines Investment
PresidentSteve DeNelsky
Life Sciences Alternative Funding (LSAF) founded in 213 is a direct investment firm based in White Plains New York. The firm focuses exclusively on providing debt capital for commercial-stage medical technology companies. The firm can allocate between USD 1M-5M per investment. The firm looks to provide flexible ?tailor-made? financing solution to companies. The firm can invest globally and is currently seeking new investment opportunities.
Life Sciences Alternative Funding
PresidentEric Desai
Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.
Greenhouse Capital Partners
Principal![Biosortia Pharmaceuticals Organisation logo](/media/orglogo/482/org/2fea84b1dfdc3629c69133c1ed3921b0bd591644.png)
Mr Kurt Dieck
Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases. We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.
Value Proposition
Pharma is looking for 3 key things:
1. Novel, never seen before, chemistry from new environments to fight chronic disease
2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects
3. New mechanisms of action to fight chronic disease in new and more effective manner
It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”. Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation. The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.
We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.
Best Regards,
Kurt Dieck
President and CEO
kdieck@biosortia.com
(614) 296-7076
![CloSys Corporation Organisation logo](/media/orglogo/482/org/b1e3423263c5ce810e94a05d90760b1699af26d7.jpg)
Kevin Dillon
We have developed the CloSys Hemostatic Device (HD) - a highly differentiated technology for vascular closure after an interventional cardiology or peripheral procedure. CloSys HD is unique in that it facilitates rapid closure but leaves NO foreign material behind in the patient. It does this using a patented technology that eliminates heparin (anti-coagulant) from a small amount of the patient's blood and re-infuses this back to the puncture site and around the entire artery. The de-heparinized blood rapidly and safely forms a clot to seal the artery naturally. There are several other unique attributes of this product. First - it is the only product that will also seal "backsticks" or inadvertant punctures that go through the other side of the artery. Backsticks are a leading cause of retroperitoneal hemorrhage. Second - it preserves immediate re-access at the same site in the advent of an emergency.
There is also an important economic value proposition offered by CloSys HD. It will have a very low cost of goods so it could be sold for a price that will allow high margins to the manufacturer and cost savings to the hospital.
We are approximately 25% of the way through a US pivotal trial and to date all performance and safety endpoints have been met. There is a highly experienced management team and exceptional Board of Directors now associated with the company.
![Kevin Dillon](/media/gravatar/482/user/29fb374e4fc80f6f2dac11838bfbfc10e0bd305c.jpg)
CloSys Corporation
CEOKaren Drexler
Astia Angels
Founder![Altravax Organisation logo](/media/orglogo/482/org/d26bf016fe18bee3b875bbd87864d90b964ef573.jpg)
Dr Sean Du
Altravax is a privately held biopharmaceutical company focused on developing first-in-class biological products to fight infectious diseases or treat other indications. The Company has a robust pipeline of candidates at various preclinical stages of development including a therapeutic vaccine against chronic hepatitis B infection. Altravax seeks investment opportunities to develop these lead candidates for clinical testing.
Altravax
Co-Founder, Chief Operator OfficerRichard Duke
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)3 not-for-profit entity committed to economic development through the creation and funding of Colorado Life Science companies. Our goal is to efficiently transform emerging life science innovations into commercial successes. First, we use a rigorous review process and advisory panel to select promising post-proof-of-concept technologies from Colorado’s outstanding research institutions and start-up companies. Second, we fund and actively manage product development while taking an equity position in existing companies and in new companies that we found with the inventors. Third, we facilitate additional seed and/or grant funding to further develop our portfolio companies technologies. By augmenting the value of these innovations, we position our portfolio companies to attract series A financing from venture capitalists and/or partnering opportunities with established pharmaceutical and biotechnology companies. We have funded 9 early stage companies since June 2010 and these companies have raised more than $30 million in additional private capital and grant funding.